Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Medtronic
Mallinckrodt
McKesson
Dow

Last Updated: August 8, 2022

Investigational Drug Information for Samatasvir


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Samatasvir?

Samatasvir is an investigational drug.

There have been 5 clinical trials for Samatasvir. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2013.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis C, Chronic. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Janssen Research & Development, LLC, and [disabled in preview].

There are twenty-five US patents protecting this investigational drug and three hundred and twelve international patents.

Recent Clinical Trials for Samatasvir
TitleSponsorPhase
Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)Merck Sharp & Dohme Corp.Phase 1
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)Janssen Research & Development, LLCPhase 2
Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)Merck Sharp & Dohme Corp.Phase 2

See all Samatasvir clinical trials

Clinical Trial Summary for Samatasvir

Top disease conditions for Samatasvir
Top clinical trial sponsors for Samatasvir

See all Samatasvir clinical trials

US Patents for Samatasvir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Samatasvir See Plans and Pricing 1',4'-thio nucleosides for the treatment of HCV IDENIX PHARMACEUTICALS LLC (Cambridge, MA) See Plans and Pricing
Samatasvir See Plans and Pricing Viral prophylaxis treatment methods and pre-exposure prophylaxis kits ELIAN LLC (Monrovia, CA) See Plans and Pricing
Samatasvir See Plans and Pricing Nucleotide and nucleoside therapeutic compositions and uses related thereto Emory University (Atlanta, GA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Samatasvir

Drugname Country Document Number Estimated Expiration Related US Patent
Samatasvir European Patent Office EP3004130 2033-06-05 See Plans and Pricing
Samatasvir World Intellectual Property Organization (WIPO) WO2014197578 2033-06-05 See Plans and Pricing
Samatasvir Australia AU2015287994 2034-07-07 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Medtronic
Mallinckrodt
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.